Duodenal ulcer disease and mild gastric ulcer. Prevention and treatment of duodenum ulcer occurring during NSAID use. Duodenal ulcerations coexisting with infectionHelicobacter pylori. Gastroesophageal reflux disease: symptomatic treatment of complaints associated with gastroesophageal reflux disease; reflux oesophagitis. Symptomatic treatment of recurrent dyspeptic complaints not related to gastrointestinal disease. Zollinger-Ellison syndrome. Prevention of bleeding from stress ulcer in severely ill patients. Prevention of recurrent bleeding from gastric and duodenal ulcers. Prevention of the Mendelson syndrome.
Composition:
1 tabl powl. contains 150 mg of Ranitidine as hydrochloride.
Action:
A specific, fast-acting histamine H receptor antagonist2. It inhibits both basic and postprandial secretion of hydrochloric acid and reduces the secretion of pepsin in gastric juice. After administration, it is well absorbed from the gastrointestinal tract. After 2 hours, it reaches its maximum concentration in the blood. It works about 12 hours. It is excreted in the urine, mainly in unchanged form. T0,5 is about 2.5-3 h.
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation.
Precautions:
Caution should be exercised in patients with hepatic impairment, in middle-aged and elderly patients with dyspeptic disorders or who have changed the nature of their discomfort. Avoid use in patients with a history of acute porphyria. The tablets contain an orange sunset which may cause allergic reactions.
Pregnancy and lactation:
During pregnancy and breastfeeding, use only if absolutely necessary.
Side effects:
Rare: hypersensitivity reactions (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, chest pain), transient changes in liver enzymes, skin rash. Very rare: leukopenia, thrombocytopenia, agranulocytosis or pancytopenia with bone marrow aplasia or hypoplasia, anaphylactic shock, confusion, depression and hallucinations (especially in seriously ill and elderly patients), headache and dizziness, transient disturbances related to involuntary movements, transient blurred vision , possibly as a result of disturbed eye accommodation, bradycardia, atrioventricular block, vasculitis, acute pancreatitis, diarrhea, hepatitis (cellular, tubular or mixed) with or without jaundice, usually transient, erythema multiforme, hair loss, joint pain and muscle, interstitial nephritis, impotence, gynecomastia.
Dosage:
Orally. Duodenal ulcer and stomach: usually 1 tabl. Twice a day or once 300 mg before bedtime, the treatment lasts 4-8 weeks. Prevention and treatment of duodenal ulcer occurring during NSAID use: 150 mg 2 times a day or once 300 mg before bedtime, treatment lasts 8-12 weeks, preventively during NSAID treatment: 150 mg 2 times a day. Duodenal ulceration coexisting with infectionHelicobacter pylori 150 mg twice daily or 300 mg once a day together with Amoxicillin (750 mg 3 times a day) and Metronidazole (500 mg 3 times a day)) for 2 weeks. For 2 consecutive weeks only ranitidine should be used; supportive treatment: 150 mg before bedtime. Gastroesophageal reflux disease: symptomatic treatment of complaints associated with gastro-oesophageal reflux - 150 mg 1-2 times a day for 2-4 weeks; in adults with reflux oesophagitis - 150 mg twice daily or 300 mg once before going to sleep for 8-12 weeks; for severe symptoms of oesophagitis - 150 mg 4 times a day for 12 weeks. Recurring dyspeptic symptoms: 150 mg 1-2 times a day for 6 weeks. Zollinger-Ellison syndrome: initial dose is 150 mg 3 times a day, up to 6 g a day. Prevention of Mendelson syndrome: 150 mg for 2 h before the start of general anesthesia, also 150 mg in the evening of the day preceding anesthesia; in obstetrics you can use 150 mg every 6 hours from the beginning of labor.Prevention of bleeding from stress ulcer in severely ill patients and recurrent bleeding in patients with peptic ulcer: 150 mg twice daily. Children: peptic ulcer - 2 mg / kg up to 4 mg / kg 2 times a day, up to 300 mg a day. Patients with renal insufficiency (creatinine clearance less than 50 ml / min) up to 150 mg per day; patients on chronic dialysis: 150 mg immediately after dialysis.